ADMA Biologics, Inc.
ASCENIV TM
Resolved
64days ago
Approval decision · May 4, 2026
What's at stake
A final FDA approval decision on ASCENIV TM for its lead indication is expected May 4, 2026.
Primary source
· SEC 8-K
verified 16h ago
“On May 4, 2026, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s label expansion supplemental Biologics License Application for ASCENIV TM to includ”